SCHEMBL6186091

SCHEMBL6186091

CS(=O)(=O)OCCCN1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
USP2 O75604 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
MMP9 P14780 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
HRH3 Q9Y5N1 13/20 0.46
KCNH2 Q12809 2/20 0.46
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CYP1A2 P05177 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15884868 0.98 ALDH1A1 (0.54) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL2077149 0.88 KDM4E (0.44) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL2075399 0.88 KDM4E (0.44) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL10554729 0.86 KDM4E (0.54) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL2078423 0.86 KDM4E (0.46) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL16109518 0.85 USP2 (0.52) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL8221324 0.81 ALDH1A1 (0.48) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL214497 0.81 HRH3 (0.49) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL21074178 0.81 LTA4H (0.42) KDM4EUSP2ALDH1A1LMNAMMP9
Hydrochloric Acid SCHEMBL16713747 0.80 MAPK1 (0.50) KDM4EUSP2ALDH1A1LMNAMMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
EP-1534703-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR ABBOTT LABORATORIES (US) 2005-06-01 EP disclosed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US disclosed
WO-2003106452-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-24 WO disclosed
EP-0921125-B1 1,3,8-Triazaspiro[4,5]decan-4-on derivatives HOFFMANN LA ROCHE (CH) 2002-01-30 EP disclosed
EP-1023285-A1 AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS TACHYKININ ANTAGONISTS Pfizer Limited (GB) 2000-08-02 EP disclosed
US-6043366-A USEFUL IN TREATING DISORDERS INVOLVING THE ORPHANIN FQ(A SEVENTEEN AMINO ACID LONG PEPTIDE) RECEPTOR. HOFFMAN-LA ROCHE INC. (US) 2000-03-28 US disclosed
EP-0921125-A1 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-06-09 EP disclosed
WO-1999001451-A1 AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS TACHYKININ ANTAGONISTS PFIZER LIMITED (GB) 1999-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MCHR1, MCHR2, MC1R KDM4E 1548/4885USP2 3491/4885ALDH1A1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.